Schering-Plough Corporation is a major U.S.-based manufacturer of pharmaceuticals. It operates in three segments: Prescription Pharmaceuticals, Animal Health, and Consumer Health Care. Schering-Plough develops products targeting on allergy, cancer, hepatitis, cardiovascular, central nervous system, respiratory system, and more.  It was founded in 1851 by Ernst Christian Friedrich Schering as Schering AG in Germany. Schering-Plough manufactured several pharmaceutical drugs, the most well-known of which were the allergy drugs Claritin and Clarinex, an anti-cholesterol drug Vytorin, and a brain tumor drug Temodar. It also developed drugs targeting on central nervous system and the respiratory system. Schering Plough also owned and operated the major foot care brand name Dr. Scholl's and the skin care line Coppertone. These also became a part of the new company. Schering-Plough was a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), a membership which is also maintained by the new Merck.

Research Grants 5 show all




Publications 3,211 show all

  • 56
    Chromatography, High Pressure Liquid/methods
  • 53
  • 46
    Dendritic Cells/immunology
  • 46
    Enzyme Inhibitors/pharmacology
  • 43
    Viral Nonstructural Proteins/antagonists & inhibitors
  • 39
  • 37
    Mass Spectrometry/methods
  • 35
  • 34
    Piperidines/chemical synthesis
  • 30
    Alkyl and Aryl Transferases/antagonists & inhibitors

Patents 6,627show all

  • 1,526
    C07D - Heterocyclic compounds
  • 1,424
    A61K - Preparations for medical, dental, or toilet purposes
  • 752
    C07K - Peptides
  • 376
    C12N - Microorganisms or enzymes
  • 335
    C07C - Acyclic or carbocyclic compounds
  • 204
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 161
    C07H - Sugars
  • 113
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 109
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 102
    Y02A - Technologies for adaptation to climate change

Clinical Trials 221show all

60Phase 245N/A39Phase 330Phase 424Phase 19Other

Contact Information

2000 Galloping Hill Road
Kenilworth, NJ 07033-0530
United States


Total FundingEmployeesLast Funding DateStatus